Kneissel M - Search Results

1

Genomic deletion of a long-range bone enhancer misregulates sclerostin in Van Buchem disease.

Loots GG, Kneissel M, Keller H, Baptist M, Chang J, Collette NM, Ovcharenko D, Plajzer-Frick I, Rubin EM. Loots GG, et al. Among authors: kneissel m. Genome Res. 2005 Jul;15(7):928-35. doi: 10.1101/gr.3437105. Epub 2005 Jun 17. Genome Res. 2005. PMID: 15965026 Free PMC article.

2

Control of the SOST bone enhancer by PTH using MEF2 transcription factors.

Leupin O, Kramer I, Collette NM, Loots GG, Natt F, Kneissel M, Keller H. Leupin O, et al. Among authors: kneissel m. J Bone Miner Res. 2007 Dec;22(12):1957-67. doi: 10.1359/jbmr.070804. J Bone Miner Res. 2007. PMID: 17696759 Free PMC article.

3

SOST is a target gene for PTH in bone.

Keller H, Kneissel M. Keller H, et al. Among authors: kneissel m. Bone. 2005 Aug;37(2):148-58. doi: 10.1016/j.bone.2005.03.018. Bone. 2005. PMID: 15946907

4

Parathyroid hormone (PTH)-induced bone gain is blunted in SOST overexpressing and deficient mice.

Kramer I, Loots GG, Studer A, Keller H, Kneissel M. Kramer I, et al. Among authors: kneissel m. J Bone Miner Res. 2010 Feb;25(2):178-89. doi: 10.1359/jbmr.090730. J Bone Miner Res. 2010. PMID: 19594304 Free PMC article.

5

Mef2c deletion in osteocytes results in increased bone mass.

Kramer I, Baertschi S, Halleux C, Keller H, Kneissel M. Kramer I, et al. Among authors: kneissel m. J Bone Miner Res. 2012 Feb;27(2):360-73. doi: 10.1002/jbmr.1492. J Bone Miner Res. 2012. PMID: 22161640 Free article.

6

Does osteocytic SOST suppression mediate PTH bone anabolism?

Kramer I, Keller H, Leupin O, Kneissel M. Kramer I, et al. Among authors: kneissel m. Trends Endocrinol Metab. 2010 Apr;21(4):237-44. doi: 10.1016/j.tem.2009.12.002. Epub 2010 Jan 13. Trends Endocrinol Metab. 2010. PMID: 20074973 Review.

7

Everolimus suppresses cancellous bone loss, bone resorption, and cathepsin K expression by osteoclasts.

Kneissel M, Luong-Nguyen NH, Baptist M, Cortesi R, Zumstein-Mecker S, Kossida S, O'Reilly T, Lane H, Susa M. Kneissel M, et al. Bone. 2004 Nov;35(5):1144-56. doi: 10.1016/j.bone.2004.07.013. Bone. 2004. PMID: 15542040

8

Reversing LRP5-dependent osteoporosis and SOST deficiency-induced sclerosing bone disorders by altering WNT signaling activity.

Chang MK, Kramer I, Keller H, Gooi JH, Collett C, Jenkins D, Ettenberg SA, Cong F, Halleux C, Kneissel M. Chang MK, et al. Among authors: kneissel m. J Bone Miner Res. 2014 Jan;29(1):29-42. doi: 10.1002/jbmr.2059. J Bone Miner Res. 2014. PMID: 23901037 Free article.

9

Osteocyte Wnt/beta-catenin signaling is required for normal bone homeostasis.

Kramer I, Halleux C, Keller H, Pegurri M, Gooi JH, Weber PB, Feng JQ, Bonewald LF, Kneissel M. Kramer I, et al. Among authors: kneissel m. Mol Cell Biol. 2010 Jun;30(12):3071-85. doi: 10.1128/MCB.01428-09. Epub 2010 Apr 19. Mol Cell Biol. 2010. PMID: 20404086 Free PMC article.

10

Sclerostin inhibition promotes TNF-dependent inflammatory joint destruction.

Wehmeyer C, Frank S, Beckmann D, Böttcher M, Cromme C, König U, Fennen M, Held A, Paruzel P, Hartmann C, Stratis A, Korb-Pap A, Kamradt T, Kramer I, van den Berg W, Kneissel M, Pap T, Dankbar B. Wehmeyer C, et al. Among authors: kneissel m. Sci Transl Med. 2016 Mar 16;8(330):330ra35. doi: 10.1126/scitranslmed.aac4351. Epub 2016 Mar 16. Sci Transl Med. 2016. PMID: 27089204

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

73 results

Search Page